Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Binding Site Group Limited currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners, which means each pending action is being reviewed by a different individual. Despite this distribution of personnel, the prosecution is limited to 2 distinct art units, suggesting technical overlap in the subject matter. HAQ, SHAFIQUL is identified as the busiest examiner for this portfolio, currently handling 1 busiest examiner pending action.
With 3 pending office actions assigned to 3 distinct examiners, the company must manage multiple prosecution styles simultaneously. However, the concentration in 2 distinct art units within the Biotechnology & Pharmaceuticals sector may offer consistency in the legal and technical standards applied to the applications. Because HAQ, SHAFIQUL is responsible for 1 busiest examiner pending action, the workload is spread across the assigned examiners. This lack of examiner concentration requires a strategy to address the specific requirements of each of the 3 distinct examiners involved in the current Biotechnology & Pharmaceuticals filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
| COOK, LISA V | 1 | 67.5% | +10.3% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17990554 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | COOK, LISA V | — |
| 17774086 | METHOD OF DETECTING OR MONITORING MINIMAL RESIDUAL DISEASE IN A MONOCLONAL GAMMOPATHY PATIENT | DUNN, LINDSAY MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18454967 | ANTIBODIES | HAQ, SHAFIQUL | — |
| 17990554 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | COOK, LISA V | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18454967 | ANTIBODIES | HAQ, SHAFIQUL | 1678 | §103 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 17990554 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | COOK, LISA V | 1642 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2022 |
| 17774086 | METHOD OF DETECTING OR MONITORING MINIMAL RESIDUAL DISEASE IN A MONOCLONAL GAMMOPATHY PATIENT | DUNN, LINDSAY MICHELLE | 1642 | §101§102§103§112Other | Non-Final OA | — | Pending | May 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Binding Site Group Limited has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Shafiqul Haq has the most, with 1 of The Binding Site Group Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
